JKT · IRRA.JK
PT Itama Ranoraya Tbk
IDR 350-IDR 4 (-1.13%)
PT Itama Ranoraya Tbk’s quoted price sits in the lower half of its reported 52-week range, 43.09% below the high.
Loading market information…
JKT · LABS.JK · IDR
Stock price
Quote as of Oct 30, 2026, 09:03 AM UTC. Cached market data; not a live quote.
One-year closing-price history · IDR. Historical prices are not a forecast.
UBC Medical Indonesia Tbk.’s quoted price sits in the lower half of its reported 52-week range, 52.69% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
UBC Medical Indonesia Tbk (LABS.JK) serves as a key supplier of medical devices throughout Indonesia. The company's operations are structured into two primary divisions: Medical Disposables and Consumables, and Diagnostics and Equipment. Its comprehensive product lineup includes advanced solutions for next-generation molecular analysis, AI-driven retina diagnostics, infectious disease detection, HPV DNA testing, real-time PCR technology, TB management systems, and newborn screening. Established in 2014, UBC Medical Indonesia Tbk is headquartered in Jakarta Timur, Jakarta, and operates as a subsidiary under the ownership of PT Optel Investama Mulia.
Latest available per-share figures in IDR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
IDR 350-IDR 4 (-1.13%)
PT Itama Ranoraya Tbk’s quoted price sits in the lower half of its reported 52-week range, 43.09% below the high.
IDR 123+IDR 1 (+0.82%)
PT Royal Prima Tbk’s quoted price sits in the upper half of its reported 52-week range, 8.21% below the high.
IDR 64-IDR 4 (-5.88%)
PT Maja Agung Latexindo Tbk’s quoted price sits in the lower half of its reported 52-week range, 44.83% below the high.
IDR 278-IDR 2 (-0.71%)
PT Diagnos Laboratorium Utama Tbk’s quoted price sits in the upper half of its reported 52-week range, 27.23% below the high.
IDR 198IDR 0 (0.0%)
PT Millennium Pharmacon International Tbk’s quoted price sits in the upper half of its reported 52-week range, 13.16% below the high.
IDR 254IDR 0 (0.0%)
PT Phapros, Tbk’s quoted price sits in the lower half of its reported 52-week range, 44.78% below the high.
IDR 24-IDR 2 (-7.69%)
PT Nanotech Indonesia Global Tbk’s quoted price sits in the lower half of its reported 52-week range, 64.18% below the high.
IDR 58-IDR 3 (-4.92%)
PT Hetzer Medical Indonesia Tbk’s quoted price sits in the lower half of its reported 52-week range, 63.06% below the high.
